Literature DB >> 25053

Hypotensive and bradycardic effects of classical alpha-sympathomimetic drugs upon intravenous administration to pentobarbitone-anaesthetized rats.

P B Timmermans, P H Fluitman, J C Mackaay, P A van Zwieten.   

Abstract

The effects of the classical alpha-sympathomimetic drugs naphazoline, tramazoline, xylometazoline, tetryzoline and oxymetazoline on blood pressure and heart rate of pentobarbitone-anaesthetized (75 mg/kg; i.p.) normotensive rats were studied following intravenous injections. With the aid of this experimental animal model a dose dependent decrease in mean arterial pressure and heart rate could be established for these agents, oxymetazoline excepted, for which only the bradycardia could be quantified. It is suggested that central alpha-adrenoceptors are involved in the mechanism of this cardiovascular inhibition in view of the most specific alpha-adrenoceptor-stimulating properties of these ddrugs. Additionally, the results indicate that the use of pentobarbitone as the anaesthetic enhances the hypotensive action of these agents, so that their pronounced peripheral vasopressive response can be overcome.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 25053

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  3 in total

1.  Participation of cardiac presynaptic alpha 2-adrenoceptors in the bradycardiac effects of clonidine and analogues.

Authors:  A de Jonge; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

Review 2.  Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 2: Cardiovascular system.

Authors:  C A Maggi; A Meli
Journal:  Experientia       Date:  1986-03-15

3.  Dexmedetomidine-induced decrease in cerebral blood flow is attenuated by verapamil in rats: a laser Doppler study.

Authors:  F Bari; G Horváth; G Benedek
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.